dc.contributor.author | Pflégr, Václav | |
dc.contributor.author | Stolaříková, Jiřina | |
dc.contributor.author | Pál, Adrián | |
dc.contributor.author | Korduláková, Jana | |
dc.contributor.author | Krátký, Martin | |
dc.date.accessioned | 2024-01-23T10:10:39Z | |
dc.date.available | 2024-01-23T10:10:39Z | |
dc.date.issued | 2023 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/2197 | |
dc.description.abstract | Background: Molecular hybridization and isostery are proven approaches in medicinal chemistry, and as such we used them to design novel compounds that we investigated as potential antimycobacterials to combat drug-resistant strains. Methods & results: Prepared N-alkyl-2-(pyrimidine-5-carbonyl)hydrazine-1-carboxamides were cyclized to N-alkyl-5-(pyrimidin-5-yl)-1,3,4-oxadiazol-2-amines along with their analogues. A total of 48 compounds were tested against Mycobacterium tuberculosis H(37)Rv, Mycobacterium avium and Mycobacterium kansasii, with oxadiazoles and C(8)-C(12) alkyls being the most effective from a concentration of 2 mu M. Multidrug-resistant strains were inhibited at same concentrations as the susceptible strain. For the most potent N-dodecyl-5-(pyrimidin-5-yl)-1,3,4-oxadiazol-2-amine, the mechanism of action related to cell wall biosynthesis was investigated. Conclusion: Pyrimidine-1,3,4-oxadiazole hybrids are unique antimycobacterial agents inhibiting mainly M. tuberculosis strains without cross-resistance to current drugs and are thus promising drug candidates. | en |
dc.language.iso | en | |
dc.relation.url | http://www.future-science.com/doi/10.4155/fmc-2023-0096 | |
dc.rights | Creative Commons Uveďte původ 4.0 International | cs |
dc.rights | Creative Commons Attribution 4.0 International | en |
dc.title | Novel pyrimidine-1,3,4-oxadiazole hybrids and their precursors as potential antimycobacterial agents | en |
dcterms.accessRights | openAccess | |
dcterms.license | https://creativecommons.org/licenses/by/4.0/legalcode | |
dc.date.updated | 2024-04-18T13:40:44Z | |
dc.subject.keyword | 1,3,4-oxadiazole | en |
dc.subject.keyword | antimycobacterial activity | en |
dc.subject.keyword | hydrazinecarboxamides | en |
dc.subject.keyword | pyrimidine | en |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU21-05-00482 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5103 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK//SVV260661 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/COOP/COOP | |
dc.date.embargoStartDate | 2024-04-18 | |
dc.type.obd | 73 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.identifier.doi | 10.4155/fmc-2023-0096 | |
dc.identifier.utWos | 001043492000001 | |
dc.identifier.eidScopus | 2-s2.0-85169180507 | |
dc.identifier.obd | 639797 | |
dc.identifier.pubmed | 37555280 | |
dc.subject.rivPrimary | 30000::30100::30104 | |
dcterms.isPartOf.name | Future Medicinal Chemistry | |
dcterms.isPartOf.issn | 1756-8919 | |
dcterms.isPartOf.journalYear | 2023 | |
dcterms.isPartOf.journalVolume | 15 | |
dcterms.isPartOf.journalIssue | 12 | |
uk.faculty.primaryId | 113 | |
uk.faculty.primaryName | Farmaceutická fakulta v Hradci Králové | cs |
uk.faculty.primaryName | Faculty of Pharmacy in Hradec Kralove | en |
uk.department.primaryId | 366 | |
uk.department.primaryName | Katedra organické a bioorganické chemie | cs |
uk.department.primaryName | Department of Organic and Bioorganic Chemistry | en |
dc.description.pageRange | 1049-1067 | |
dc.type.obdHierarchyCs | ČLÁNEK V ČASOPISU::článek v časopisu::původní článek | cs |
dc.type.obdHierarchyEn | JOURNAL ARTICLE::journal article::original article | en |
dc.type.obdHierarchyCode | 73::152::206 | en |
uk.displayTitle | Novel pyrimidine-1,3,4-oxadiazole hybrids and their precursors as potential antimycobacterial agents | en |